159 related articles for article (PubMed ID: 28460455)
1. CCDC106 promotes non-small cell lung cancer cell proliferation.
Zhang X; Zheng Q; Wang C; Zhou H; Jiang G; Miao Y; Zhang Y; Liu Y; Li Q; Qiu X; Wang E
Oncotarget; 2017 Apr; 8(16):26662-26670. PubMed ID: 28460455
[TBL] [Abstract][Full Text] [Related]
2. Kctd20 promotes the development of non-small cell lung cancer through activating Fak/AKT pathway and predicts poor overall survival of patients.
Zhang X; Zhou H; Cai L; Fan C; Liu Y; Wang L; Li Q; Miao Y
Mol Carcinog; 2017 Sep; 56(9):2058-2065. PubMed ID: 28398603
[TBL] [Abstract][Full Text] [Related]
3. CCDC85B promotes non-small cell lung cancer cell proliferation and invasion.
Feng Y; Gao Y; Yu J; Jiang G; Zhang X; Lin X; Han Q; Rong X; Xu H; Li Q; Qiu X; Wang E
Mol Carcinog; 2019 Jan; 58(1):126-134. PubMed ID: 30242906
[TBL] [Abstract][Full Text] [Related]
4. TRIM44 promotes proliferation and metastasis in non‑small cell lung cancer via mTOR signaling pathway.
Xing Y; Meng Q; Chen X; Zhao Y; Liu W; Hu J; Xue F; Wang X; Cai L
Oncotarget; 2016 May; 7(21):30479-91. PubMed ID: 27058415
[TBL] [Abstract][Full Text] [Related]
5. The depletion of PinX1 involved in the tumorigenesis of non-small cell lung cancer promotes cell proliferation via p15/cyclin D1 pathway.
Tian XP; Jin XH; Li M; Huang WJ; Xie D; Zhang JX
Mol Cancer; 2017 Apr; 16(1):74. PubMed ID: 28372542
[TBL] [Abstract][Full Text] [Related]
6. Hyperphosphorylation of ribosomal protein S6 predicts unfavorable clinical survival in non-small cell lung cancer.
Chen B; Tan Z; Gao J; Wu W; Liu L; Jin W; Cao Y; Zhao S; Zhang W; Qiu Z; Liu D; Mo X; Li W
J Exp Clin Cancer Res; 2015 Oct; 34():126. PubMed ID: 26490682
[TBL] [Abstract][Full Text] [Related]
7. CK2-mediated CCDC106 phosphorylation is required for p53 degradation in cancer progression.
Ning Y; Wang C; Liu X; Du Y; Liu S; Liu K; Zhou J; Zhou C
J Exp Clin Cancer Res; 2019 Mar; 38(1):131. PubMed ID: 30885251
[TBL] [Abstract][Full Text] [Related]
8. CCDC106 promotes the proliferation and invasion of ovarian cancer cells by suppressing p21 transcription through a p53-independent pathway.
Zhao N; Wang C; Guo P; Hou J; Yang H; Lan T; Zhou Y; Li J; Bhawal UK; Liu Y
Bioengineered; 2022 Apr; 13(4):10956-10972. PubMed ID: 35484984
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of CRKL correlates with poor prognosis and cell proliferation in non-small cell lung cancer.
Wang Y; Dong QZ; Fu L; Stoecker M; Wang E; Wang EH
Mol Carcinog; 2013 Nov; 52(11):890-9. PubMed ID: 22753141
[TBL] [Abstract][Full Text] [Related]
10. Farnesoid X receptor, a novel proto-oncogene in non-small cell lung cancer, promotes tumor growth via directly transactivating CCND1.
You W; Chen B; Liu X; Xue S; Qin H; Jiang H
Sci Rep; 2017 Apr; 7(1):591. PubMed ID: 28377627
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
[TBL] [Abstract][Full Text] [Related]
12. EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer.
Geng J; Li X; Zhou Z; Wu CL; Dai M; Bai X
Cancer Lett; 2015 Apr; 359(2):275-87. PubMed ID: 25633838
[TBL] [Abstract][Full Text] [Related]
13. ZNF452 facilitates tumor proliferation and invasion via activating AKT-GSK3β signaling pathway and predicts poor prognosis of non-small cell lung cancer patients.
Zhang X; Zhou H; Zhang Y; Cai L; Jiang G; Li A; Miao Y; Li Q; Qiu X; Wang E
Oncotarget; 2017 Jun; 8(24):38863-38875. PubMed ID: 28418919
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of Bcl-2 and cyclin A2 on adverse recurrence-free survival in stage I non-small cell lung cancer.
Ko E; Kim Y; Cho EY; Han J; Shim YM; Park J; Kim DH
Ann Surg Oncol; 2013 Mar; 20(3):1005-12. PubMed ID: 23115005
[TBL] [Abstract][Full Text] [Related]
15. Lasp2 enhances tumor invasion via facilitating phosphorylation of FAK and predicts poor overall survival of non-small cell lung cancer patients.
Zhang X; Cai L; Zhou H; Liu Y; Fan C; Wang L; Li A; Miao Y; Li Q; Qiu X; Wang E
Mol Carcinog; 2017 Dec; 56(12):2558-2565. PubMed ID: 28667800
[TBL] [Abstract][Full Text] [Related]
16. LncRNA16 is a potential biomarker for diagnosis of early-stage lung cancer that promotes cell proliferation by regulating the cell cycle.
Zhu H; Zhang L; Yan S; Li W; Cui J; Zhu M; Xia N; Yang Y; Yuan J; Chen X; Luo J; Chen R; Xing R; Lu Y; Wu N
Oncotarget; 2017 Jan; 8(5):7867-7877. PubMed ID: 27999202
[TBL] [Abstract][Full Text] [Related]
17. DDX5 promotes proliferation and tumorigenesis of non-small-cell lung cancer cells by activating β-catenin signaling pathway.
Wang Z; Luo Z; Zhou L; Li X; Jiang T; Fu E
Cancer Sci; 2015 Oct; 106(10):1303-12. PubMed ID: 26212035
[TBL] [Abstract][Full Text] [Related]
18. ANKRD22 promotes progression of non-small cell lung cancer through transcriptional up-regulation of E2F1.
Yin J; Fu W; Dai L; Jiang Z; Liao H; Chen W; Pan L; Zhao J
Sci Rep; 2017 Jun; 7(1):4430. PubMed ID: 28667340
[TBL] [Abstract][Full Text] [Related]
19. [Interleukin 7 and its receptor promote cell proliferation and induce lymphangiogenesis in non-small cell lung cancer].
Ming J; Zhang QF; Jiang YD; Jiang GC; Qiu XS
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):511-8. PubMed ID: 23157741
[TBL] [Abstract][Full Text] [Related]
20. ING5 inhibits cancer aggressiveness via preventing EMT and is a potential prognostic biomarker for lung cancer.
Zhang F; Zhang X; Meng J; Zhao Y; Liu X; Liu Y; Wang Y; Li Y; Sun Y; Wang Z; Mei Q; Zhang T
Oncotarget; 2015 Jun; 6(18):16239-52. PubMed ID: 25938545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
